Monday, October 28, 2024 3:23:32 PM
exwannabe,
Doesn’t take a genius to figure out that price manipulation over time without the right kind of news was going to continue no matter what they did. Hiring someone to give the appearance that uplisting might take place soon was likely the impetus but the reality was/is that even a reverse split would come under attack without sufficient news ie finalized and digitized Flaskworks production model that allows reimbursement models to work. This is especially true where off label process use due to biomarker identification from proteomics might lead to more rapid label extensions for approval. Initial testing of artisan method digitization during ramp up will be a good way to test for any oversight issues.
Franchise modeling with Flaskworks seems likely and digitization with assigned tracking codes likely sends all info simultaneously for tracking similar to how packages are tracked. Best wishes.
Doesn’t take a genius to figure out that price manipulation over time without the right kind of news was going to continue no matter what they did. Hiring someone to give the appearance that uplisting might take place soon was likely the impetus but the reality was/is that even a reverse split would come under attack without sufficient news ie finalized and digitized Flaskworks production model that allows reimbursement models to work. This is especially true where off label process use due to biomarker identification from proteomics might lead to more rapid label extensions for approval. Initial testing of artisan method digitization during ramp up will be a good way to test for any oversight issues.
Franchise modeling with Flaskworks seems likely and digitization with assigned tracking codes likely sends all info simultaneously for tracking similar to how packages are tracked. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
